Last Updated: November 16, 2026

RYZNEUTA Drug Profile

« Back to Dashboard


Summary for Tradename: RYZNEUTA
High Confidence Patents:0
Applicants:1
BLAs:1
Pharmacology for RYZNEUTA
Established Pharmacologic ClassLeukocyte Growth Factor
Chemical StructureColony-Stimulating Factors
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for RYZNEUTA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for RYZNEUTA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for RYZNEUTA Derived from Patent Text Search

No patents found based on company disclosures

RYZNEUTA Market Dynamics and Financial Trajectory: Efbemalenograstim Alfa Analysis

Last updated: September 1, 2026

RYZNEUTA, or efbemalenograstim alfa, is a long-acting granulocyte colony-stimulating factor (G-CSF) developed for chemotherapy-induced neutropenia. Its commercial opportunity is meaningful but constrained by a mature market dominated by pegfilgrastim, multiple pegfilgrastim biosimilars, established hospital contracts, and reimbursement pressure.

The product’s financial trajectory depends on three variables: U.S. market penetration, pricing relative to pegfilgrastim and biosimilars, and expansion through licensing partnerships. Public companies involved with RYZNEUTA have not disclosed audited, product-level revenue sufficient to calculate sales, margins, or a reliable consensus forecast.

What is RYZNEUTA and how does efbemalenograstim alfa work?

RYZNEUTA is the brand name for efbemalenograstim alfa, also known as F-627. It is a long-acting recombinant G-CSF intended to reduce the duration of chemotherapy-induced neutropenia and the incidence of febrile neutropenia in adults receiving myelosuppressive chemotherapy.

Attribute RYZNEUTA
Active ingredient Efbemalenograstim alfa
Product type Long-acting recombinant G-CSF
Primary use Prevention of chemotherapy-induced neutropenia
Administration Subcutaneous injection
Dosing pattern Once per chemotherapy cycle, generally after chemotherapy
Developer Evive Biotech
U.S. commercialization Acrotech Biopharma
Main competitors Pegfilgrastim products, filgrastim, eflapegrastim and other G-CSF products
Regulatory status FDA-approved biologic; approved in China
FDA pathway Biologics License Application
Orange Book status Not applicable as a biologic

RYZNEUTA is designed to compete with long-acting pegylated G-CSF products rather than with short-acting filgrastim alone. Its commercial value is based on cycle-level prophylaxis, reduced administration frequency and use in oncology treatment protocols.

What is the FDA regulatory status of RYZNEUTA?

The FDA approved RYZNEUTA in 2023 for reducing the duration of neutropenia in adult patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.[1]

The labeled administration is a single subcutaneous dose during each chemotherapy cycle. The product is generally administered approximately 24 hours after cytotoxic chemotherapy and is not intended for administration shortly before or during chemotherapy.[1]

China approved efbemalenograstim alfa before or around the U.S. launch period, giving Evive an initial commercial market outside the United States. The China market has a larger domestic pharmaceutical manufacturing base but also has centralized procurement and pricing controls that can limit biologic margins.

FDA regulatory milestones

Milestone Timing
Clinical development Phase 3 development in chemotherapy-induced neutropenia
FDA approval 2023
Commercial product RYZNEUTA
U.S. commercial partner Acrotech Biopharma
Regulatory category Biologic
Interchangeability designation No publicly established interchangeable biosimilar designation

The FDA label identifies typical risks associated with G-CSF products, including splenic rupture, acute respiratory distress syndrome, serious allergic reactions, sickle-cell complications in susceptible patients, capillary leak syndrome, aortitis and leukocytosis.[1]

How large is the market for long-acting G-CSF products?

The relevant market is the global supportive-care market for prevention of chemotherapy-induced neutropenia. Pegfilgrastim remains the reference product, but the market has shifted from a single branded product toward a multi-product purchasing environment.

Key demand drivers include:

  • Continued use of myelosuppressive chemotherapy in breast, lung, lymphoma, ovarian and other cancers.
  • Clinical guideline support for primary prophylaxis in regimens with substantial febrile-neutropenia risk.
  • Preference for once-per-cycle administration over daily filgrastim in many treatment settings.
  • Expansion of biosimilar and follow-on G-CSF competition.
  • Hospital and oncology-practice efforts to reduce drug acquisition cost.
  • Use of biosimilars and authorized products in payer and group-purchasing contracts.

The market is less attractive than it was before pegfilgrastim competition. Neulasta generated multibillion-dollar annual sales before biosimilar entry, but current market value is distributed across Neulasta, pegfilgrastim biosimilars, on-body delivery systems, filgrastim products and newer long-acting agents.

How does RYZNEUTA compare with pegfilgrastim and competing G-CSF products?

RYZNEUTA competes primarily on clinical comparability, administration convenience, supply reliability and net price. It does not have an obvious mechanism-based advantage that would eliminate the need for contracting against pegfilgrastim biosimilars.

Product category Representative products Administration Competitive position
Originator pegfilgrastim Neulasta Once per cycle Established reference product
Pegfilgrastim biosimilars Fulphila, Ziextenzo, Nyvepria, Stimufend, Fylnetra, Udenyca and others Once per cycle Strong price competition
Long-acting non-pegylated or alternative G-CSF RYZNEUTA, Rolvedon Once per cycle Differentiation through product design and commercial contracting
Short-acting filgrastim Neupogen and biosimilars Daily or repeated dosing Lower unit cost, higher administration burden
On-body delivery Neulasta Onpro and related systems Automated post-chemotherapy delivery Convenience and workflow differentiation

RYZNEUTA’s principal commercial challenge is that treatment guidelines generally address the need for G-CSF prophylaxis rather than requiring a particular long-acting molecule. That gives oncology practices and payers substantial latitude to substitute among clinically accepted products.

What are the main market dynamics affecting RYZNEUTA sales?

Biosimilar and generic-like price pressure

Although RYZNEUTA is a biologic and does not face conventional generic substitution, its market behaves in part like a mature commodity market. Pegfilgrastim biosimilars create reference-price pressure, particularly in hospital outpatient departments, integrated delivery networks and large oncology practices.

The product must therefore compete on net price rather than list price. Rebates, chargeback structures, distributor terms and payer formulary placement can materially affect realized revenue.

Buy-and-bill economics

Many oncology G-CSF products are administered in physician offices or hospital outpatient departments under medical-benefit reimbursement. The economics depend on the spread between acquisition cost and payer reimbursement, inventory risk, payment timing and practice-specific purchasing contracts.

A product with a lower acquisition price can gain share even if clinical differentiation is limited. Conversely, a product with a premium list price may require rebates or other concessions to achieve formulary access.

Administration and workflow

RYZNEUTA is administered once per chemotherapy cycle, like pegfilgrastim. This limits its convenience advantage over the dominant long-acting category. Its greater practical differentiation is against daily filgrastim and against products with more burdensome administration or supply limitations.

The product’s commercial message is therefore likely to focus on efficacy, safety, predictable post-chemotherapy dosing, availability and net economics.

China pricing and procurement

China provides a large addressable oncology population, but government procurement and reimbursement negotiations can compress prices. Domestic and regional competitors may also receive preferential access in some channels. China can support volume growth without producing U.S.-level revenue per dose.

What is the financial trajectory for RYZNEUTA?

Public information supports a staged commercial trajectory rather than a high-confidence product-sales forecast.

Phase Financial characteristics
Pre-launch High development and regulatory spending; no recurring product revenue
Initial launch Sales and marketing investment, distributor buildout, contract negotiations and inventory formation
Early commercial period Revenue growth depends on formulary wins and conversion from pegfilgrastim or filgrastim
Scale-up Gross margin improves if manufacturing utilization increases and discounting remains controlled
Mature phase Growth likely tracks oncology treatment volume, share gains and geographic expansion rather than category expansion

No publicly available audited filing establishes RYZNEUTA’s standalone revenue, gross profit, operating income or cash contribution. Evive Biotech has not provided a sufficiently detailed public segment report for a reliable product-level income statement. U.S. commercialization through Acrotech also limits visibility because partnership economics, transfer prices, royalties and milestone payments have not been publicly disclosed in a detailed financial schedule.

Likely revenue drivers

The largest potential revenue drivers are:

  1. U.S. conversion from pegfilgrastim and filgrastim products.
  2. China volume growth.
  3. Expansion into additional markets through licensing or distribution.
  4. Improved manufacturing utilization.
  5. Retention of price relative to pegfilgrastim biosimilars.
  6. Adoption by community oncology practices and hospital systems.

Margin risks

RYZNEUTA’s gross-margin profile may be pressured by:

  • Contracting discounts required to secure preferred status.
  • Distributor and group-purchasing fees.
  • Competition from pegfilgrastim biosimilars.
  • Manufacturing scale-up costs.
  • Cold-chain logistics.
  • Regulatory and post-marketing commitments.
  • Royalty or profit-sharing obligations under commercial agreements.

The highest-value commercial outcome would be a differentiated position with limited discounting. A volume-led strategy with heavy rebates could produce prescription growth without proportional operating-profit growth.

Which companies are challenging RYZNEUTA in the G-CSF market?

RYZNEUTA faces competition from originator manufacturers, biosimilar developers and oncology-focused specialty pharmaceutical companies.

Key competing companies and products

  • Amgen: Neulasta and Neulasta Onpro.
  • Sandoz and other biosimilar developers: pegfilgrastim biosimilar products.
  • Fresenius Kabi: pegfilgrastim products and oncology supportive-care offerings.
  • Coherus BioSciences: Udenyca.
  • Pfizer and related commercial entities: biosimilar and supportive-care products.
  • Spectrum Pharmaceuticals: Rolvedon, or eflapegrastim-xnst.
  • Teva and other generic manufacturers: filgrastim and related products.
  • Acrotech Biopharma: U.S. commercialization of RYZNEUTA.

Competition is strongest where payers and providers use preferred-product contracts. The product with the strongest net price, dependable supply and workable reimbursement often wins share, even when clinical outcomes are broadly comparable.

What patents protect RYZNEUTA and when could biosimilar competition begin?

RYZNEUTA is protected primarily through biologic manufacturing, formulation, composition, use and regulatory exclusivity rights rather than through Orange Book-listed small-molecule patents.

The product does not have an Orange Book patent listing because the Orange Book is principally used for approved drug products subject to abbreviated new drug application procedures. Biologic patent disputes are generally addressed through the Biologics Price Competition and Innovation Act, the Purple Book and patent-information exchange procedures.[2]

The FDA provides 12 years of reference-product exclusivity for qualifying biologics, subject to statutory rules and pediatric exclusivity. The precise biosimilar-entry date depends on the reference-product approval date, applicable exclusivity, patent settlements and the timing of any biosimilar applications.[3]

Patent and exclusivity considerations

Issue RYZNEUTA implication
Orange Book listing Generally not applicable
Purple Book listing Relevant biologic reference-product record
BPCIA exclusivity Potential 12-year reference-product exclusivity framework
Paragraph IV challenge Not the standard legal pathway for a biologic
Biosimilar litigation Possible under BPCIA patent procedures
Formulation patents May extend protection if valid and commercially relevant
Manufacturing patents Potentially important because complex biologic production is difficult to replicate
Method-of-use patents May cover chemotherapy-induced neutropenia indications or dosing approaches
Settlement agreements No major publicly established settlement is identified in the cited public materials

The practical barrier to competition may be higher than the statutory exclusivity period suggests. A biosimilar developer must demonstrate analytical similarity, establish an acceptable manufacturing process and secure oncology-channel access. Manufacturing know-how, cell-line control, process consistency and supply reliability can delay or weaken entry even after core regulatory exclusivity expires.

Are there Paragraph IV challenges or RYZNEUTA patent lawsuits?

Paragraph IV litigation is associated with Hatch-Waxman generic-drug applications and is not the primary pathway for RYZNEUTA because it is a biologic. A biosimilar applicant could instead use the BPCIA patent-information and litigation framework.

No major publicly reported RYZNEUTA patent litigation or settlement has been established in the cited public sources. That does not eliminate future litigation risk. Potential disputes could involve:

  • Composition and fusion-protein claims.
  • Cell-line and production-process claims.
  • Purification and formulation claims.
  • Dosing after cytotoxic chemotherapy.
  • Manufacturing consistency and comparability.
  • Patent-term adjustment or regulatory-exclusivity calculations.

What is the commercial outlook for RYZNEUTA?

RYZNEUTA has a credible commercial opportunity because it entered an established market with a recognized clinical need and a recurring treatment-cycle use case. Its ceiling is limited by the strength of pegfilgrastim biosimilars and the absence of a clearly dominant clinical or workflow advantage over other once-per-cycle G-CSF products.

Bull case

The product achieves preferred status in major U.S. oncology networks, wins share from higher-priced pegfilgrastim products, expands in China and secures additional international licensing deals. Manufacturing scale improves gross margin, while pricing remains above the lowest-cost biosimilars.

Base case

RYZNEUTA becomes a niche or mid-tier long-acting G-CSF product. Sales grow through selected oncology practices and regional contracts, but broad formulary adoption requires substantial discounting. Revenue increases, while profitability depends on commercial scale and partner economics.

Downside case

Payers and providers consolidate around low-cost pegfilgrastim biosimilars. RYZNEUTA requires aggressive rebates, resulting in limited net-sales growth and weak operating leverage. Manufacturing, partnership and launch costs delay profitability.

What revenue exposure does RYZNEUTA create for its commercial partners?

RYZNEUTA creates exposure to oncology supportive care, but the revenue profile differs by participant.

  • Evive Biotech has exposure to product royalties, milestone payments, supply revenue or profit-sharing, depending on regional agreements.
  • Acrotech Biopharma has exposure to U.S. sales, commercial expenses, inventory and reimbursement execution.
  • Manufacturing partners may receive supply revenue but carry production and quality-control obligations.
  • Distributors and oncology providers capture channel economics rather than pharmaceutical product revenue.

Because product-level disclosures are limited, RYZNEUTA should not be valued using headline market size alone. The relevant metrics are net price per administered dose, annual treatment cycles, market share, gross-to-net deductions, partner revenue share and cost of goods.

Key Takeaways

  • RYZNEUTA is efbemalenograstim alfa, a long-acting G-CSF for chemotherapy-induced neutropenia.
  • The FDA approved the product in 2023; China is also a commercial market.
  • Acrotech Biopharma is the U.S. commercial partner.
  • The addressable market is large but mature and heavily exposed to pegfilgrastim biosimilar pricing.
  • RYZNEUTA’s once-per-cycle dosing competes directly with pegfilgrastim rather than creating a wholly new treatment category.
  • Public filings do not provide sufficient product-level revenue or profitability data to calculate a reliable financial forecast.
  • Biologic exclusivity, manufacturing know-how and BPCIA procedures are more relevant than Orange Book or Paragraph IV analysis.
  • The most likely base case is gradual market penetration with significant contracting pressure.
  • Commercial success depends more on formulary access, net price and supply reliability than on broad category growth.

FAQs About RYZNEUTA Market and Financial Outlook

Is RYZNEUTA the same as pegfilgrastim?

No. RYZNEUTA is efbemalenograstim alfa, while pegfilgrastim is a pegylated form of recombinant G-CSF. Both are long-acting products used to reduce chemotherapy-induced neutropenia, but they are different biologic molecules.

Who markets RYZNEUTA in the United States?

Acrotech Biopharma is the U.S. commercial partner associated with RYZNEUTA. Evive Biotech is the originating developer.

Can a generic substitute for RYZNEUTA automatically at the pharmacy?

No. RYZNEUTA is a biologic. Any competing product would generally need to follow the biosimilar pathway, and automatic substitution depends on an FDA interchangeability designation and state law.

Does RYZNEUTA have an Orange Book patent expiry date?

No conventional Orange Book patent-expiry analysis applies because RYZNEUTA is a biologic. Relevant protection involves biologic exclusivity, Purple Book status, patents and BPCIA procedures.

What is the biggest financial risk to RYZNEUTA?

The main financial risk is rapid price compression from pegfilgrastim biosimilars. If RYZNEUTA requires deep discounts to obtain oncology-provider and payer access, prescription growth may not translate into strong revenue or operating profit.

References

  1. U.S. Food and Drug Administration. (2023). RYZNEUTA (efbemalenograstim alfa) prescribing information.
  2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
  3. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Patient Protection and Affordable Care Act, Pub. L. No. 111-148.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.